检索结果-南通市图书馆

Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer:an open-label,randomized controlled phase 3 trial(ORIENT-3)

引用

Cancer Communications 2022年第12期42卷 1314-1330页

作者： Yuankai Shi Lin Wu Xinmin Yu Puyuan Xing Yan Wang Jianying Zhou Airong Wang Jianhua Shi Yi Hu Ziping Wang Guangyu An Yong Fang Sanyuan Sun Caicun Zhou Changli Wang Feng Ye Xingya Li Junye Wang Mengzhao Wang Yunpeng Liu Yanqiu Zhao Ying Yuan Jifeng Feng Zhendong Chen Jindong Shi Tao Sun Gang Wu Yongqian Shu Qisen Guo Yi Zhang Yong Song Shucai Zhang Yuan Chen Wei Li Hongrui Niu Wenwei Hu Lijun Wang Jianan Huang Yang Zhang Ying Cheng Zhengdong Wu Bo Peng Jiya Sun Christoph Mancao Yanqi Wang Luyao Sun Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsBeijingP.R.China Department II of Thoracic Medicine Hunan Cancer HospitalChangshaHunanP.R.China Department of Medical Oncology Zhejiang Cancer HospitalHangzhouZhejiangP.R.China Department of Respiratory Diseases The First Affiliated HospitalCollege of MedicineZhejiang UniversityHangzhouZhejiangP.R.China The Third Department of Chemotherapy Weihai Municipal HospitalWeihaiShandongP.R.China Department of Medical Oncology Linyi Cancer HospitalLinyiShandongP.R.China Oncology Department General Hospital of Chinese People’s Liberation ArmyBeijingP.R.China Department of Chest Medicine Beijing Cancer HospitalBeijingP.R.China Department of Oncology Beijing Chao-Yang HospitalCapital Medical UniversityBeijingP.R.China Department of Medical Oncology Sir Run Run Shaw HospitalZhejiang UniversityHangzhouZhejiangP.R.China Department of Medical Oncology Xuzhou Central HospitalXuzhou Medical UniversityXuzhouJiangsuP.R.China Department of Medical Oncology Shanghai Pulmonary HospitalTongji UniversityShanghaiP.R.China Department of Lung Cancer Tianjin Medical University Cancer Institute and HospitalTianjinP.R.China Department of Medical Oncology Cancer HospitalThe First Affiliated Hospital of Xiamen UniversitySchool of MedicineXiamen UniversityThe Third Clinical Medical CollegeFujian Medical UniversityXiamenFujianP.R.China Department of Medical Oncology The First Affiliated Hospital of Zhengzhou UniversityZhengzhouHenanP.R.China Department of Oncology Affiliated Hospital of Jining Medical UniversityJiningShandongP.R.China Department of Respiratory and Critical Care Medicine Peking Union Medical College HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijingP.R.China Department of Medical Oncology Key L

Background:Treatment options for Chinese patients with locally advanced or metastatic squamous-cell non-small-cell lung cancer(sqNSCLC)after failure of first-line chemotherapy are *** study(ORIENT-3)aimed to evaluate the efficacy and safety of sintilimab versus docetaxel as second-line treatment in patients with locally advanced or metastatic ***:ORIENT-3 was an open-label,multicenter,randomized controlled phase 3 trial that recruited patients with stage IIIB/IIIC/IV sqNSCLC after failure with first-line platinum-based *** were randomized in a 1:1 ratio to receive either 200 mg of sintilimab or 75 mg/m^(2) of docetaxel intravenously every 3 weeks,stratified by the Eastern Cooperative Oncology Group performance *** primary endpoint was overall survival(OS)in the full analysis set(FAS).Secondary endpoints included progression-free survival(PFS),objective response rate(ORR),disease control rate(DCR),duration of response(DoR)and ***:Between August 25,2017,and November 7,2018,290 patients were *** FAS,10 patients fromthe docetaxel armwere *** OS was 11.79(n=145;95%confidence interval[CI],10.28-15.57)months with sintilimab versus 8.25(n=135;95%CI,6.47-9.82)months with docetaxel(hazard ratio[HR]:0.74;95%CI,0.56-0.96;P=0.025).Sintilimab treatment significantly prolonged PFS(median 4.30 vs.2.79 months;HR:0.52;95%CI,0.39-0.68;P<0.001)and showed higher ORR(25.50%vs.2.20%,P<0.001)and DCR(65.50%vs.37.80%,P<0.001)than the docetaxel *** median DoRwas 12.45(95%CI,4.86-25.33)months in the sintilimab arm and 4.14(95%CI,1.41-7.23)months in the docetaxel arm(P=0.045).Treatment-related adverse events of grade≥3were reported in 26(18.1%)patients in the sintilimab arm and 47(36.2%)patients in the docetaxel *** biomarker analysis showed potential predictive values of expression levels of two transcription factors,including OVOL2(HR:0.35;P<0.001)and CTCF(HR:3.50;P<0.001),for sintilimab treatme

关键词： Non-small cell lung cancer Carcinoma squamous cell Sintilimab Immunotherapy Survival Randomized controlled trial

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Expert Consensus on Diagnosis and Treatment of End-Stage Liver Disease Complicated with Infections

引用

Infectious Diseases & Immunity 2022年第3期2卷 168-178页

作者： Qin Ning Tao Chen Guiqiang Wang Dong Xu Yanyan Yu Qing Mao Taisheng Li Lanjuan Li Jun Li Xiaoju Lu Jiabin Li Zhiwei Li Wenhong Zhang Yonghong Xiao Qinghua Meng Yuqiang Mi Jia Shang Yunsong Yu Yingren Zhao Caiyan Zhao Hong Zhao Jianrong Huang Jie Peng Hong Tang Xiaoping Tang Jinhua Hu Bijie Hu Wei Guo Bo Zheng Baiyi Chen Yuexin Zhang Jia Wei Jifang Sheng Zhi Chen Minggui Wang Qing Xie Yuming Wang Fu-Sheng Wang Jinlin Hou Zhongping Duan Lai Wei Jidong Jia Chinese Society of Infectious Disease of Chinese Medical Association Department of Infectious Disease Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Department of Infectious Disease Center for Liver DiseasePeking University First HospitalBeijing 100034China Department of Infectious Diseases Southwest HospitalArmy Medical UniversityChongqing 400038China Department of Infectious Diseases Peking Union Medical College HospitalPeking Union Medical College and Chinese Academy of Medical SciencesBeijing 100730China State Key Laboratory for Diagnosis and Treatment of Infectious Diseases Collaborative Innovation Center for Diagnosis and Treatment of Infectious DiseasesThe First Affiliated HospitalSchool of MedicineZhejiang UniversityHangzhou 310003China Department of Infectious Disease The First Affiliated Hospital with Nanjing Medical UniversityNanjing 210029China Center of Infectious Diseases West China Hospital of Sichuan UniversityChengdu 610041China Department of Infectious Diseases First Affiliated Hospital of Anhui Medical UniversityHefei 230031China Department of Infectious Diseases Shengjing HospitalAffiliated Hospital of China Medical UniversityShenyang 110801China Department of Infectious Diseases Institute of Infectious DiseasesHuashan HospitalFudan UniversityShanghai 200040China Department of Severe Liver Diseases Beijing Youan HospitalCapital Medical UniversityBeijing 100069China Nankai University Second People’s Hospital Tianjin 300071China Department of Infectious Disease People’s Hospital of Henan ProvinceZhengzhou 450003China Department of Infectious Diseases Sir Run Run Shaw HospitalZhejiang University School of MedicineHangzhou 310020China Department of Infectious Diseases First Affiliated Hospital of Xi’an Jiaotong UniversityXi’an 710061China Department of Infectious Diseases Third Affiliated Hospital of Hebei Medical UniversityShijiazhuang 050051China State Key Laboratory of Organ Failure Research Guangdong Provincial Key Laboratory of Viral Hepatitis ResearchDepartment o

End-stage liver disease(ESLD)is a life-threatening clinical syndrome that markedly increases mortality in patients with *** patients with ESLD,infections can induce or aggravate the occurrence of liver ***,infections are among the most common complications of disease *** is a lack of working procedure for early diagnosis and appropriate management for patients with ESLD complicated by infections as well as local and international guidelines or *** consensus assembled up-to-date knowledge and experience across Chinese colleagues,providing data on principles as well as working procedures for the diagnosis and treatment of patients with ESLD complicated by infections.

关键词： Consensus Diagnosis End stage of liver disease Infection Therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The real-world study of the clinical characteristics,diagnosis,and treatment of advanced pancreatic cancer in China

引用

Journal of Pancreatology 2024年第1期7卷 1-9页

作者： Jiujie Cui Qihan Fu Xiaobing Chen Yanling Wang Qi Li Feng Wang Zhihua Li Guanghai Dai Yusheng Wang Hongmei Zhang Houjie Liang Jun Zhou Liu Yang Fenghua Wang Leizhen Zheng Xiaofeng Chen Ping Gong Jiang Liu Ying Yuan Lin Wang Yuejuan Cheng Jun Zhang Yuhong Zhou Weijian Guo Xianbao Zhan Zhengyun Zou Da Li Shan Zeng Enxiao Li Zhiwei Li Zan Teng Dan Cao Jie Kan Jianping Xiong Ming Quan Jiayu Yao Haiyan Yang Liwei Wang Department of Medical Oncology Renji HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghaiChina Department of Medical Oncology The First Affiliated HospitalCollege of MedicineZhejiang UniversityHangzhouChina Department of Medical Oncology Affiliated Cancer Hospital of Zhengzhou UniversityHenan Cancer HospitalZhengzhouChina Department of Medical Oncology Shanghai General HospitalShanghai Jiao Tong UniversityShanghaiChina Department of Medical Oncology The First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina Department of Medical Oncology Sun Yat-sen Medical Hospital Sun Yat-sen UniversityGuangzhouChina Medical Oncology Chinese PLA General HospitalBeijingChina Department of Gastrointestinal Oncology Shanxi Provincial Cancer HospitalAffiliated to Shanxi Medical UniversityTaiyuanChina Department of Clinical Oncology Xijing HospitalAir Force Medical UniversityXi’anChina Department of Oncology and Southwest Cancer Center Southwest HospitalThird Military Medical University(Army Military Medical University)ChongqingChina Department of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing)Peking University Cancer Hospital&InstituteBeijingChina Cancer Center Department of Medical OncologyZhejiang Provincial People’s HospitalPeople’s Hospital of Hangzhou Medical CollegeHangzhouChina Department of Medical Oncology Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongChina Oncology Department Xin Hua Hospital Affiliated to Shanghai JiaoTong University School of MedicineShanghaiChina Department of Oncology the First Affiliated Hospital with Nanjing Medical UniversityNanjingChina Department of Oncology The First Affiliated HospitalSchool of MedicineShihezi UniversityShiheziChina Department of Oncology People’s Hospital of Xinjiang Uygur Autonomous RegionXinjiangChina Department of Medical Oncology t

Objective:Real-world diagnostic and treatment data for pancreatic cancer in China are *** such,the present study investigated the clinical characteristics,diagnosis,and treatment of advanced pancreatic cancer(including locally advanced and metastatic disease)in the Hospital-based Advanced Pancreatic Cancer Cohort in China of the China Pancreas Data Center ***:A total of 5349 Chinese patients with advanced pancreatic cancer were identified from a *** entire course of real-world pancreatic cancer management was ***:The proportion of patients with advanced pancreatic cancer was higher among males than females(62.4%vs 37.6%,respectively).Patients typically had a history of hypertension(30.8%),diabetes(21.6%),and cholangitis(20.2%).Abdominal pain(51.6%),abdominal distension(27.1%),jaundice(20.1%),and weight loss(16.3%)were the main symptoms observed in patients with advanced pancreatic cancer in this *** carbohydrate antigen(CA)19-9 is one of the most common tumor *** the present study,2562 patients underwent first-line *** median progression-free survival(PFS)for patients undergoing first-line therapy was 4.1 *** major options for first-line therapy included gemcitabine(GEM)plus S-1(GS/X)(23.4%),nab-paclitaxel plus GEM(AG)(18.1%),oxaliplatin,irinotecan,and leucovorin-modulated fluorouracil(FOLFIRINOX;11.9%),nab-paclitaxel plus S-1(AS)(8.9%),and GEM combined with oxaliplatin/cisplatin(GEMOX/GP)(7.6%).The AS and GS/X regimens were associated with the highest PFS ***:This is the first study to report multicenter,real-world data regarding advanced pancreatic cancer in *** revealed that real-world treatment options differed from guideline recommendations,and PFS was shorter than that in previously reported *** intelligent follow-up systems and standardizing diagnosis and treatment of pancreatic cancer is recommended.

关键词： Advanced pancreatic cancer China Pancreas Data Center Chinese First-line regimens Real-world study

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations

引用

The Innovation 2024年第6期5卷 100-116页

作者： Wenxian Wang Bin Lian Chunwei Xu Qian Wang Ziming Li Nan Zheng Aijun Liu Jinpu Yu Wenzhao Zhong Zhijie Wang Yongchang Zhang Jingjing Liu Shirong Zhang Xiuyu Cai Anwen Liu Wen Li Lili Mao Ping Zhan Hongbing Liu Tangfeng Lv Liyun Miao Lingfeng Min Yu Chen Jingping Yuan Feng Wang Zhansheng Jiang Gen Lin Long Huang Xingxiang Pu Rongbo Lin Weifeng Liu Chuangzhou Rao Dongqing Lv Zongyang Yu Xiaoyan Li Chuanhao Tang Chengzhi Zhou Junping Zhang Junli Xue Hui Guo Qian Chu Rui Meng Xuewen Liu Jingxun Wu Rui Zhang Jin Zhou Zhengfei Zhu Yongheng Li Hong Qiu Fan Xia Yuanyuan Lu Xiaofeng Chen Jian Feng Rui Ge Enyong Dai Yu Han Weiwei Pan Fei Pang Xin Huang Meizhen Hu Qing Hao Kai Wang Fan Wu Binbin Song Bingwei Xu Liping Wang Youcai Zhu Li Lin Yanru Xie Xinqing Lin Jing Cai Ling Xu Jisheng Li Xiaodong Jiao Kainan Li Jia Wei Huijing Feng Lin Wang Yingying Du Wang Yao Xuefei Shi Xiaomin Niu Dongmei Yuan Yanwen Yao Jianhui Huang Yue Feng Yinbin Zhang Pingli Sun Hong Wang Mingxiang Ye Dong Wang Zhaofeng Wang Yue Hao Zhen Wang Bin Wan Donglai Lv Shengjie Yang Jin Kang Jiatao Zhang Chao Zhang Wenfeng Li Jianfei Fu Lizhi Wu Shijie Lan Juanjuan Ou Lin Shi Zhanqiang Zhai Yina Wang Bihui Li Zhang Zhang Ke Wang Xuelei Ma Zhongwu Li Zhefeng Liu Nong Yang Lin Wu Huijuan Wang Gu Jin Guansong Wang Jiandong Wang Hubing Shi Meiyu Fang Yong Fang Yuan Li Xiaojia Wang Jing Chen Yiping Zhang Xixu Zhu Yi Shen Shenglin Ma Biyun Wang Yong Song Zhengbo Song Wenfeng Fang Yuanzhi Lu Lu Si Department of Chemotherapy Chinese Academy of Sciences University Cancer Hospital(Zhejiang Cancer Hospital)HangzhouZhejiang 310022P.R.China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of Melanoma and SarcomaPeking University Cancer Hospital&InstituteBeijing 100142P.R.China Institute of Cancer and Basic Medicine(ICBM) Chinese Academy of SciencesHangzhouZhejiang 310022P.R.China Department of Respiratory Medicine Affiliated Jinling HospitalMedical School of Nanjing UniversityNanjingJiangsu 210002P.R.China Department of Respiratory Medicine Affiliated Hospital of Nanjing University of Chinese MedicineJiangsu Province Hospital of Chinese MedicineNanjingJiangsu 210029P.R.China Department of Shanghai Lung Cancer Center Shanghai Chest HospitalShanghai Jiao Tong UniversityShanghai 200030P.R.China Beijing Key Laboratory of Mental Disorders National Clinical Research Center for Mental Disorders&National Center for Mental DisordersBeijing Anding HospitalCapital Medical UniversityBeijing 200030China Advanced Innovation Center for Human Brain Protection Capital Medical UniversityBeijing 200030China Senior Department of Pathology the 7th Medical Center of PLA General HospitalBeijing 100700P.R.China Department of Cancer Molecular Diagnostics Core Tianjin Medical University Cancer Institute and HospitalTianjin 300060P.R.China Guangdong Lung Cancer Institute Guangdong Provincial Laboratory of Translational Medicine in Lung CancerGuangdong Provincial People’s HospitalGuangdong Academy of Medical SciencesSchool of MedicineGuangzhouGuangdong 510080P.R.China State Key Laboratory of Molecular Oncology Department of Medical OncologyNational Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021P.R.China Department of Medical Oncology Lung Cancer and Gastrointestinal UnitHunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School

The BRAF gene is an important signaling molecule in human cells that is involved in the regulation of cell growth,differentiation,and *** the BRAF gene mutates,it can lead to abnormal activation of the signaling pathway,which promotes cell proliferation,inhibits cell apoptosis,and ultimately contributes to the occurrence and development of *** mutations are widely present in various cancers,including malignant melanoma,thyroid cancer,colorectal cancer,non-small cell lung cancer,and hairy cell leukemia,among *** is an important target for the treatment of various solid tumors,and targeted combination therapies,represented by BRAF inhibitors,have become one of the main treatment modalities for a variety of BRAF-mutation-positive solid tumors.

关键词： BRAF diagnosis treatment

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

CACA Guidelines for Holistic Integrative Management of Breast Cancer

引用

Holistic Integrative Oncology 2022年第1期1卷 76-126页

作者： Jiong Wu Daiming Fan Zhimin Shao Binghe Xu Guosheng Ren Zefei Jiang Yongsheng Wang Feng Jin Jin Zhang Qingyuan Zhang Fei Ma Jinli Ma Zhonghua Wang Shusen Wang Xiaojia Wang Shu Wang Haibo Wang Tao Wang Xiang Wang Jing Wang Jia Wang Biyun Wang Li Fu Hongyuan Li Yehui Shi Lu Gan Yunjiang Liu Jian Liu Zhenzhen Liu Qiang Liu Qiang Sun Wenwu Cheng Keda Yu Zhongsheng Tong Xinhong Wu Chuangui Song Jianguo Zhang Jian Zhang Junjie Li Bin Li Man Li Huiping Li Wentao Yang Hongjian Yang Benlong Yang Hong Bu Juping Shen Zhenzhou Shen Yiding Chen Ceshi Chen Da Pang Zhimin Fan Ying Zheng Xiaoli Yu Guangyu Liu Xichun Hu Yiqun Ling Jinhai Tang Yongmei Yin Cuizhi Geng Peng Yuan Yajia Gu Cai Chang Xuchen Cao Yuan Sheng Yuanxi Huang Jian Huang Weijun Peng Xiaohua Zeng Yuntao Xie Ning Liao Committee of Breast Cancer Society,Chinese Anti-Cancer Association Key Laboratory of Breast Cancer in Shanghai Department of Breast SurgeryFudan University Shanghai Cancer CenterShanghai Medical College of Fudan UniversityShanghaiChina Department of Oncology Shanghai Medical College of Fudan UniversityShanghaiChina Department of Gastroenterology Beijing Chaoyang HospitalCapital Medical UniversityBeijingChina State key Laboratory of Cancer Biology National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive DiseasesFourth Military Medical UniversityXi’anChina National Cancer Center/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina Department of Endocrine and Breast Surgery The First Affliated Hospital of Chongqing Medical UniversityYuzhongChongqingChina Medicine-Oncology The Affliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese People’s Liberation Army)BeijingChina Breast Disease Center Shandong Cancer HospitalJinanChina Department of Breast Surgery The First Affliated Hospital of China Medical UniversityShenyangChina The 3rd Department of Breast Cancer China Tianjin Breast Cancer PreventionTreatment and Research CenterTianjin Medical University Cancer Institute and HospitalNational Clinical Research Center of CancerTianjinChina Harbin Medical University Cancer Hospital HarbinChina Department of Radiation Oncology Fudan University Shanghai Cancer CenterShanghai Medical College of Fudan UniversityShanghaiChina Sun Yat-Sen University Cancer Center GuangzhouChina Zhejiang Cancer Hospital HangzhouChina Breast Center Peking University People’s HospitalBeijingChina Department of Breast Center The Affliated Hospital of Qingdao UniversityShandongChina Department of Oncology Fifth Medical Center of Chinese PLA General HospitalBeijingChina Department of Breast Surgical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina Departmen

Purpose:Breast cancer is now the most common malignant tumor *** one-fourth of female cancer patients all over the world sufer from breast *** about one in six female cancer deaths worldwide is caused by breast *** terms of absolute numbers of cases and deaths,China ranks frst in the *** CACA Guidelines for Holistic Integrative Management of Breast Cancer were edited to help improve the diagnosis and comprehensive treatment in ***:The Grading of Recommendations Assessment,Development and Evaluation(GRADE)was used to classify evidence and ***:The CACA Guidelines for Holistic Integrative Management of Breast Cancer include the epidemiology of breast cancer,breast cancer screening,breast cancer diagnosis,early breast cancer treatment,advanced breast cancer treatment,follow-up,rehabilitation,and traditional Chinese medicine treatment of breast cancer ***:We to standardize the diagnosis and treatment of breast cancer in China through the formulation of the CACA Guidelines.

关键词： Epidemiology of breast cancer Breast cancer screening Breast cancer diagnosis Early breast cancer treatment Advanced breast cancer treatment Traditional Chinese medicine treatment of breast cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

One-year status of hepatic venous pressure gradient measurement from 85 hospitals in China

引用

Portal Hypertension & Cirrhosis 2024年第2期3卷 116-123页

作者： Jitao Wang Ting Cui Linpeng Zhang Zhiping Yan Lei Li Jinjun Chen Junhui Sun Hua Xiang He Zhu Hao Wu Jiancuo Gengzang Feng Zhang Wei Wu Guohong Cao Wuhua Guo Haibin Shi Hui Xue Guangjun Huang Qiang Yu Meng Niu Huiling Xiang Derun Kong Wei Gou Xuefeng Luo Fuliang He Min Yuan Wei Liu Yong Wang Hongjie Hu Xiaoli Zhu Tao Yu Qinxue Sun Wei Qu Ting Lu Deqiang Ma Li Zhang Jun Ma Jun Yang Ketao Mu Xiaoliang Zhu Kai Xiong Huiguo Ding Shengjuan Yao Mingsheng Huang Fang Wang Zexin Wang Yong Huang Jianan Li Hongfeng Yi Birun Huang Zhongwei Zhao Duiping Feng Yanming Lei Changlong Hou Wenbo Guo Shirong Liu Gaojun Teng Kangshun Zhu Fan Wu Xiaogang Hu Wenfeng Zhang Shaoqi Yang Zhouchao Hu Pengfei Pang Shaowu Zhuang Weidong Wang Qingliang Zhu Kunpeng Zhang Chengyu Liu Dongliang Li Chao Ma Hong Jiang Xingong Zhao Weixin Ren Zhiwei Wang Lei Yu Fuhuang Lin Chaoguang Yan Feng Wang Lei Yu Hui Huan Wenyong Shen Shaofei He Chengda Zhang Jinlun Bao Jiangtao Liu Jun Wu Jianbo Zhao Jian Zhang Xiaolong Qi Hebei Provincial Key Laboratory of Cirrhosis&Portal Hypertension Xingtai People's HospitalXingtaiHebeiChina Center of Portal Hypertension Department of RadiologyZhongda HospitalSchool of MedicineSoutheast UniversityNanjingJiangsuChina Department of Interventional Therapy Beijing Shijitan Hospital Affiliated to Capital Medical UniversityBeijingChina Department of Intervention Taiyuan Third People's HospitalTaiyuanShanxiChina Department of Intervention Zhongshan Hospital Affiliated to Fudan UniversityShanghaiChina Department of Interventional Medicine The First Hospital of Lanzhou UniversityLanzhouGansuChina Department of Infectious Diseases Nanfang Hospital of Southern Medical UniversityGuangzhouGuangdongChina Hepatobiliary and Pancreatic Intervention Center The First Affiliated Hospital of Zhejiang University School of MedicineHangzhouZhejiangChina Interventional Vascular Surgery Hunan Provincial People's HospitalChangshaHunanChina Department of Intervention Sixth People's Hospital of ShenyangShenyangLiaoningChina Department of Gastroenterology West China Hospital of Sichuan UniversityChengduSichuanChina Department of Intervention The Fourth People's Hospital of Qinghai ProvinceXiningQinghaiChina Department of Gastroenterology Nanjing Drum Tower HospitalNanjingJiangsuChina Department of Gastroenterology The First Affiliated Hospital of Wenzhou Medical UniversityWenzhouZhejiangChina Department of Radiology Shulan(Hangzhou)HospitalHangzhouZhejiangChina Department of Intervention Mengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhouFujianChina Department of Interventional Radiology The First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsuChina Department of Gastroenterology The First Affiliated Hospital of Xi'an Jiaotong UniversityXi'anShaanxiChina Department of Gastroenterology Shandong Provincial Hospital Affiliated to Shandong First Medical UniversityJinanShandongChina Department of Interventional Radiology Fifth Medical Center

Aims:Surveys and research on the applications of the hepatic venous pressure gradient(HVPG)are important for understanding the current status and future development of this technology in *** article aimed to investigate the status of hepatic venous pressure gradient measurement in China in ***:We investigated the overall status of HVPG technology in China-including hospital distribution,hospital level,annual number of cases,catheters used,average cost,indications,and current challenges by using online *** counting the number and percentages of cases of these results,we hope to clarify the current status of HVPG measurements in ***:According to the survey,85 hospitals in China used HVPG technology in 2022 distributed across 29 provinces.A total of 4989 HVPG measurements were performed in all of the surveyed hospitals in 2022,of which 2813 cases(56.4%)were measured *** average cost of HVPG measurement was 5646.8±2327.9 *** the clinical teams who performed the measurements(sometimes multiple per hospital),94.3%(82/87)used the balloon method,and the majority of the teams(72.4%,63/87)used embolectomy ***:This survey clarified the clinical application status of HVPG in China and confirmed that some medical institutions in China have established a foundation for this *** is still necessary to continue promoting and popularizing this technology in the future.

关键词： application status hepatic vein pressure gradient questionnaire survey

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Extension Protocol for the Investigation on Nutrition Status and Clinical Outcome of Patients with Common Cancers in China(INSCOC)Study:2021 update

引用

Journal of Nutritional Oncology 2022年第2期7卷 64-74页

作者： Hong Xia Xu Chun Hua Song Liang Yu Yin Chang Wang Zhen Ming Fu Zeng Qing Guo Yuan Lin Ying Ying Shi Wen Hu Yi Ba Su Yi Li Zeng Ning Li Kun Hua Wang Jing Wu Ying He Jia Jun Yang Cong Hua Xie Fu Xiang Zhou Xin Xia Song Gong Yan Chen Wen Jun Ma Su Xia Luo Zi Hua Chen Zhi Kang Chen Ming Hua Cong Hu Ma Chun Ling Zhou Wei Wang Qi Luo Yong Mei Shi Yu Mei Qi Hai Ping Jiang Wen Xian Guan Jun Qiang Chen Xiang Hua Wu Jia Xin Chen Yu Fang Lan Zhou Yong Dong Feng Rong Shao Tan Tao Li Jun Wen Ou Qing Chuan Zhao Jian Xiong Wu Min Weng Qing Hua Yao Ya Yin Yu Quan Jun Lyu Hong Qiu Ming Liu Wei Li Han Ping Shi The Investigation on Nutrition Status and Clinical Outcome of Common Cancers(INSCOC)Group Department of Nutrition Daping HospitalArmy Medical University(Third Military Medical University)Chongqing 400042China Department of Epidemiology College of Public HealthZhengzhou UniversityZhengzhou 450001HenanChina Cancer Center of the First Hospital of Jilin University Changchun 130021Jilin China Cancer Center Renmin Hospital of Wuhan UniversityWuhan 430060HubeiChina Department of Medical Oncology Fujian Cancer HospitalFujian Medical University Cancer HospitalFuzhou 350014FujianChina Department of Gastrointestinal Surgery Affiliated Tumor Hospital of Guangxi Medical UniversityNanning 530021GuangxiChina Department of Surgery The First Affiliated Hospital of SunYat-Sen UniversityGuangzhou 510080GuangdongChina Department of Clinical Nutrition West China Hospital of Sichuan UniversityChengdu 610041SichuanChina Department of Gastrointestinal Oncology Tianjin Medical University Cancer Institute and HospitalNational Clinical Research Center for CancerTianjin Key Laboratory of Cancer Prevention and TherapyTianjin 300060China Department of Nutrition and Metabolism of Oncology The First Affiliated Hospital of University of Science and Technology of ChinaAnhui Provincial Cancer HospitalHefei 230031AnhuiChina Department of Clinical Nutrition The First Hospital of Hebei Medical UniversityShijiazhuang 050031HebeiChina Department of Gastrointestinal Surgery Institute of GastroenterologyThe First Affiliated Hospital of Kunming Medical UniversityKunming 650032YunnanChina Department of Clinical Nutrition The First Affiliated Hospital of Zhejiang Chinese Medical UniversityZhejiang Provincial Hospital of Traditional Chinese MedicineHangzhou 310006ZhejiangChina Department of Clinical Nutrition Chongqing General HospitalChongqing 400014China Department of Colorectal and Anal Surgery Huizhou Municipal Central HospitalHuizhou 516001GuangdongChina Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan UniversityWuhan 430071HubeiChina Department of Oncology Xingtai Peo

Background Malnutrition is common in patients with cancer,and this adversely affects the survival and quality of life of *** Society for Nutritional Oncology issued a multi-center,large-scale,long-term follow-up prospective study,the Investigation on Nutrition Status and Clinical Outcome of Patients with Common Cancers in China(INSCOC study)since *** is an extension to the previous 2013-2020 study *** study still sought to:①address the prognostic impact of nutritional factors and quality of life on cancer patient survival;②describe the overall and cancer-specific incidence and/or distribution of malnutrition and different measurements of patient quality of *** and study design This is an observational,multi-centered,hospital-based prospective cohort *** collection will be performed at baseline(within 48 hours after patient admission),during the hospital stay and 30 days after hospital ***-up will be conducted for 1-20 years after *** primary outcome will be the all-cause mortality/overall survival,and secondary outcomes will be the length of hospital stay and costs of *** factors will include demographic characteristics,tumor characteristics,information about chronic diseases,hematological measurements(e.g.,red blood cell count,total lymphocyte counts,hemoglobin,albumin,prealbumin,creatinine,C-reactive protein,IL-6),anthropometric measurements(e.g.,height,weight,arm circumference,arm muscle circumference,triceps skinfold thickness,and waist circumference),body composition parameters,PG-SGA scores,quality of life(as indicated by the QLQ-C30 questionnaire),muscle mass(as indicated by the calf circumference),muscle strength(as indicated by the handgrip strength),muscle function(as indicated by the six-meter walking speed test)and physical status assessments(as indicated by the Karnofsky Performance Status scores).This clinical study protocol was approved by local Ethics Committees of

关键词： Cancer Malnutrition Nutritional status Nutritional assessment Survival Patient-Generated Subjective Global Assessment

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：